Compare IDN & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | CING |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.0M | 93.1M |
| IPO Year | 2014 | N/A |
| Metric | IDN | CING |
|---|---|---|
| Price | $5.37 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.33 | ★ $37.00 |
| AVG Volume (30 Days) | 96.2K | ★ 563.8K |
| Earning Date | 03-19-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $4,433,454.00 | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $12.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.30 | $3.20 |
| 52 Week High | $7.48 | $11.89 |
| Indicator | IDN | CING |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 48.32 |
| Support Level | $5.12 | $3.77 |
| Resistance Level | $5.74 | $7.92 |
| Average True Range (ATR) | 0.27 | 1.06 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 51.59 | 17.71 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.